Insider Buying: TherapeuticsMD Inc (NASDAQ:TXMD) Insider Purchases 10,000 Shares of Stock

Share on StockTwits

TherapeuticsMD Inc (NASDAQ:TXMD) insider John C.K. Iv Milligan acquired 10,000 shares of the stock in a transaction on Friday, August 16th. The stock was bought at an average price of $2.93 per share, with a total value of $29,300.00. Following the completion of the acquisition, the insider now directly owns 1,472,419 shares of the company’s stock, valued at $4,314,187.67. The purchase was disclosed in a filing with the SEC, which is available at this link.

John C.K. Iv Milligan also recently made the following trade(s):

  • On Monday, August 12th, John C.K. Iv Milligan acquired 15,000 shares of TherapeuticsMD stock. The stock was bought at an average price of $3.16 per share, with a total value of $47,400.00.

TXMD stock opened at $2.78 on Thursday. The firm has a 50 day moving average price of $2.49 and a 200-day moving average price of $3.85. TherapeuticsMD Inc has a 52-week low of $1.82 and a 52-week high of $6.94. The firm has a market capitalization of $680.25 million, a price-to-earnings ratio of -4.71 and a beta of 1.90. The company has a debt-to-equity ratio of 24.29, a quick ratio of 4.99 and a current ratio of 5.17.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Tuesday, August 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.01). TherapeuticsMD had a negative net margin of 913.07% and a negative return on equity of 212.57%. The business had revenue of $6.08 million for the quarter, compared to analysts’ expectations of $5.12 million. During the same quarter in the previous year, the business posted ($0.15) earnings per share. TherapeuticsMD’s revenue for the quarter was up 60.0% on a year-over-year basis. As a group, sell-side analysts forecast that TherapeuticsMD Inc will post -0.73 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Lido Advisors LLC raised its holdings in TherapeuticsMD by 29.0% in the 2nd quarter. Lido Advisors LLC now owns 17,178 shares of the company’s stock worth $44,000 after acquiring an additional 3,865 shares during the last quarter. Metropolitan Life Insurance Co NY grew its position in TherapeuticsMD by 8.2% in the 1st quarter. Metropolitan Life Insurance Co NY now owns 60,906 shares of the company’s stock worth $296,000 after purchasing an additional 4,627 shares during the period. Beaumont Financial Partners LLC grew its position in TherapeuticsMD by 19.5% in the 1st quarter. Beaumont Financial Partners LLC now owns 35,000 shares of the company’s stock worth $170,000 after purchasing an additional 5,700 shares during the period. Advisor Group Inc. grew its position in TherapeuticsMD by 73.2% in the 2nd quarter. Advisor Group Inc. now owns 13,960 shares of the company’s stock worth $36,000 after purchasing an additional 5,900 shares during the period. Finally, Greenwood Capital Associates LLC grew its position in TherapeuticsMD by 2.2% in the 1st quarter. Greenwood Capital Associates LLC now owns 278,858 shares of the company’s stock worth $1,358,000 after purchasing an additional 5,947 shares during the period. Institutional investors own 81.05% of the company’s stock.

Several research firms have recently issued reports on TXMD. JPMorgan Chase & Co. lowered their target price on shares of TherapeuticsMD from $8.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, June 11th. ValuEngine upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Noble Financial reiterated a “buy” rating and set a $13.00 target price on shares of TherapeuticsMD in a report on Monday, August 12th. Cowen lowered their target price on shares of TherapeuticsMD from $16.00 to $9.00 and set an “outperform” rating for the company in a report on Tuesday, June 11th. Finally, Zacks Investment Research upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Tuesday, May 14th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $9.28.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

See Also: Return on Equity (ROE)

Insider Buying and Selling by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Citadel Advisors LLC Makes New Investment in SPDR Portfolio Long Term Corporate Bond ETF
Citadel Advisors LLC Makes New Investment in SPDR Portfolio Long Term Corporate Bond ETF
Citadel Advisors LLC Has $21.24 Million Position in Cable One Inc
Citadel Advisors LLC Has $21.24 Million Position in Cable One Inc
Citadel Advisors LLC Raises Stock Holdings in SITE Centers Corp.
Citadel Advisors LLC Raises Stock Holdings in SITE Centers Corp.
Citadel Advisors LLC Sells 172,873 Shares of Telephone & Data Systems, Inc.
Citadel Advisors LLC Sells 172,873 Shares of Telephone & Data Systems, Inc.
Citadel Advisors LLC Sells 1,224,750 Shares of Hudbay Minerals Inc
Citadel Advisors LLC Sells 1,224,750 Shares of Hudbay Minerals Inc
Citadel Advisors LLC Acquires 4,838 Shares of First Interstate Bancsystem Inc
Citadel Advisors LLC Acquires 4,838 Shares of First Interstate Bancsystem Inc


© 2006-2019 Ticker Report